HOUSTON - Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotechnology company with a market capitalization of $3.1 million, has announced continued progress in its clinical trials for cancer treatments.

Holdings provides an update from the Company’s ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and ...

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease Reports Continued Patient Progress from Phase ...

Auron Therapeutics has raised a $27 million Series B financing that it will use to initiate clinical development of its lead experimental drug, AUTX-703, in blood cancers.

Acute Myeloid Leukemia (AML) is a hematological malignancy characterized by the rapid, uncontrolled growth of immature myeloid cells, leading to bone marrow ...

Researchers determine a complex immune infiltrate pattern based on a newly constructed immune map developed using pancreatic ...

Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...

Researchers from the QIMR Berghofer Medical Research Institute in Queensland, Australia and Emory University have shown that a potential new targeted therapy for childhood brain cancer was effective ...

Cancer is swiftly becoming a major health issue in India, affecting both urban and rural populations due to various factors.

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research.